Condition: HIV-1-infection · Pneumocystis Pneumonia · Sponsor: Instituto Nacional de Enfermedades Respiratorias
Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV/AIDS, often severe and potentially fatal. While trimethoprim/sulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.
This description comes directly from the study's public registry record.
Xavier Flores, MD · (+52 55) 5940 2110 · xavier.flores@cieni.org.mx
Xavier Flores, MD · (+52 55) 5666 7985 · xavier.flores@cieni.org.mx
Always discuss trial participation with your own doctor first.
| Center for Research in Infectious Diseases (CIENI) | Mexico City, Tlalpan, Mexico | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06691321